Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
A drug used at the maximum tolerated dose can exert a strong selective pressure on cancer cells leading to resistance. In this study, the authors demonstrate the efficacy of using low dose of multiple drugs for preventing and treating resistance to EGFR tyrosine kinase inhibitors in NSCLC cells.
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fa274e19e6774a2dbd7ad05e9103dbab |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fa274e19e6774a2dbd7ad05e9103dbab |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fa274e19e6774a2dbd7ad05e9103dbab2021-12-02T18:02:51ZMultiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours10.1038/s41467-020-16952-92041-1723https://doaj.org/article/fa274e19e6774a2dbd7ad05e9103dbab2020-06-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-16952-9https://doaj.org/toc/2041-1723A drug used at the maximum tolerated dose can exert a strong selective pressure on cancer cells leading to resistance. In this study, the authors demonstrate the efficacy of using low dose of multiple drugs for preventing and treating resistance to EGFR tyrosine kinase inhibitors in NSCLC cells.João M. Fernandes NetoErnest NadalEvert BosdrieszSalo N. OoftLourdes FarreChelsea McLeanSjoerd KlarenbeekAnouk JurgensHannes HagenLiqin WangEnriqueta FelipAlex Martinez-MartiAugust VidalEmile VoestLodewyk F. A. WesselsOlaf van TellingenAlberto VillanuevaRené BernardsNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-9 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q João M. Fernandes Neto Ernest Nadal Evert Bosdriesz Salo N. Ooft Lourdes Farre Chelsea McLean Sjoerd Klarenbeek Anouk Jurgens Hannes Hagen Liqin Wang Enriqueta Felip Alex Martinez-Marti August Vidal Emile Voest Lodewyk F. A. Wessels Olaf van Tellingen Alberto Villanueva René Bernards Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours |
| description |
A drug used at the maximum tolerated dose can exert a strong selective pressure on cancer cells leading to resistance. In this study, the authors demonstrate the efficacy of using low dose of multiple drugs for preventing and treating resistance to EGFR tyrosine kinase inhibitors in NSCLC cells. |
| format |
article |
| author |
João M. Fernandes Neto Ernest Nadal Evert Bosdriesz Salo N. Ooft Lourdes Farre Chelsea McLean Sjoerd Klarenbeek Anouk Jurgens Hannes Hagen Liqin Wang Enriqueta Felip Alex Martinez-Marti August Vidal Emile Voest Lodewyk F. A. Wessels Olaf van Tellingen Alberto Villanueva René Bernards |
| author_facet |
João M. Fernandes Neto Ernest Nadal Evert Bosdriesz Salo N. Ooft Lourdes Farre Chelsea McLean Sjoerd Klarenbeek Anouk Jurgens Hannes Hagen Liqin Wang Enriqueta Felip Alex Martinez-Marti August Vidal Emile Voest Lodewyk F. A. Wessels Olaf van Tellingen Alberto Villanueva René Bernards |
| author_sort |
João M. Fernandes Neto |
| title |
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours |
| title_short |
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours |
| title_full |
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours |
| title_fullStr |
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours |
| title_full_unstemmed |
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours |
| title_sort |
multiple low dose therapy as an effective strategy to treat egfr inhibitor-resistant nsclc tumours |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/fa274e19e6774a2dbd7ad05e9103dbab |
| work_keys_str_mv |
AT joaomfernandesneto multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT ernestnadal multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT evertbosdriesz multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT salonooft multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT lourdesfarre multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT chelseamclean multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT sjoerdklarenbeek multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT anoukjurgens multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT hanneshagen multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT liqinwang multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT enriquetafelip multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT alexmartinezmarti multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT augustvidal multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT emilevoest multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT lodewykfawessels multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT olafvantellingen multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT albertovillanueva multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours AT renebernards multiplelowdosetherapyasaneffectivestrategytotreategfrinhibitorresistantnsclctumours |
| _version_ |
1718378905598951424 |